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Abstract 33 
The best characterized signaling pathway downstream of the transforming growth 34 
factor  (TGF-) pathway is through SMAD2 and SMAD3. However, TGF- also 35 
induces phosphorylation of SMAD1 and SMAD5, but the mechanism of this 36 
phosphorylation and its functional relevance is  not known. Here, we show that TGF-37 -induced SMAD1/5 phosphorylation requires members of two classes of type I 38 
receptor, TGFBR1 and ACVR1, and establish a new paradigm for receptor activation 39 
where TGFBR1 phosphorylates and activates ACVR1, which phosphorylates 40 
SMAD1/5. We demonstrate the biological significance of this pathway by showing 41 
that approximately a quarter of the TGF--induced transcriptome depends on 42 
SMAD1/5 signaling, with major early transcriptional targets being the ID genes. 43 
Finally, we show that TGF--induced epithelial-to-mesenchymal transition requires 44 
signaling via both the SMAD3 and SMAD1/5 pathways, with SMAD1/5 signaling 45 
being essential to induce ID1. Therefore, combinatorial signaling via both SMAD 46 
pathways is essential for the full TGF--induced transcriptional program and 47 
physiological responses. 48 
  49 
 3 
Introduction  50 
 51 
Members of the transforming growth factor  (TGF-) family of ligands, which 52 
includes the TGF-s, Activins, NODAL, BMPs and GDFs, have pleiotropic effects on 53 
cell behavior ranging from germ layer specification and patterning in embryonic 54 
development, to tissue homoestasis and regeneration in adults (Massague, 2012, 55 
Morikawa et al., 2016, Wu and Hill, 2009). TGF- family signaling is also 56 
deregulated in a number of human diseases through mutation or altered expression of 57 
either the ligands or downstream signaling pathway components (Miller and Hill, 58 
2016). In this context, the most widely studied pathology is cancer (Bellomo et al., 59 
2016, Massague, 2008, Meulmeester and Ten Dijke, 2011, Wakefield and Hill, 2013), 60 
where TGF- itself has both tumor suppressive and tumor promoting effects 61 
(Massague, 2008). At early stages of cancer TGF-’s tumor suppressive effects 62 
dominate, such as its cytostatic and pro-apoptotic functions (Padua and Massague, 63 
2009). As tumors develop, however, mutations in key components of the pathway or 64 
downstream target genes allow the tumor to evade TGF-’s tumor suppressive 65 
effects, whilst remaining sensitive to its tumor promoting activities. TGF- directly 66 
promotes the oncogenic potential of tumor cells, for example by driving epithelial-to-67 
mesenchymal transition (EMT), a hallmark of cancer that enhances cell invasion and 68 
migration, and also increases the frequency of tumor-initating cancer stem cells 69 
(Massague, 2008, Ye and Weinberg, 2015). TGF-’s dual role in cancer thus provides 70 
an excellent example of how diverse responses can be elicited by a single ligand.  71 
 The TGF- family ligands all signal via a common mechanism, initiated by 72 
ligand binding to two cell surface serine/threonine kinase receptors, the type II and 73 
type I receptors. In the receptor complex, the type II receptors phosphorylate and 74 
activate the type I receptors (Wrana et al., 1994). These in turn phosphorylate the 75 
downstream effectors of the pathway, the receptor-regulated SMADs (R-SMADs) on 76 
two serines in an SXS motif at their extreme C-terminus. Phosphorylated R-SMADs 77 
form complexes with the common SMAD, SMAD4, which accumulate in the nucleus 78 
and directly regulate the transcription of target genes, leading to new programs of 79 
gene expression (Shi and Massague, 2003). In the classic view of TGF- family 80 
signaling there are two branches, characterized by distinct combinations of type II and 81 
type I receptors, and the recruitment of specific R-SMADs to particular type I 82 
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receptors (Wakefield and Hill, 2013, Shi and Massague, 2003). One branch is 83 
activated by TGF-, Activins and NODAL and is mediated via the type I receptors 84 
TGFBR1, ACVR1B and ACVR1C (also known as ALK5, ALK4 and ALK7 85 
respectively), which phosphorylate SMAD2 and 3. The other is activated by BMPs 86 
and GDFs, and is mediated via ACVRL1, ACVR1, BMPR1A and BMPR1B (also 87 
known as ALK1, ALK2, ALK3 and ALK6 respectively), which phosphorylate 88 
SMAD1, 5 and 9 (Miller and Hill, 2016).  89 
In general, while this pairing between type I receptors and R-SMADs broadly 90 
fits the assignment of specific ligands to the different branches of TGF- family 91 
signaling, it is an oversimplification. For example, ACVR1 is now described as a 92 
BMP receptor, but early work indicated that it could bind Activin and TGF- 93 
(Massague, 1996, Miettinen et al., 1994), and very recently it has been shown to 94 
signal downstream of Activin in the context of the disease, fibrodysplasia ossificans 95 
progressiva (Hatsell et al., 2015, Hino et al., 2015). Furthermore, ACVRL1, a type I 96 
receptor that recognizes BMP9 and 10, also transduces TGF- signals in endothelial 97 
cells (Pardali et al., 2010) by phosphorylating SMAD1/5 in parallel with the canonical 98 
TGF--induced phosphorylation of SMAD2/3 (Goumans et al., 2002, Goumans et al., 99 
2003). This SMAD1/5 arm of TGF- signaling has also been shown to occur in a 100 
wide range of other cell types, including epithelial cells, fibroblasts and cancer cell 101 
lines, which do not express ACVRL1 (Liu et al., 1998, Daly et al., 2008, Liu et al., 102 
2009, Wrighton et al., 2009).  103 
Important questions concerning this noncanonical TGF--induced SMAD1/5  104 
phosphorylation remain unanswered. First, the mechanism by which TGF- induces 105 
SMAD1/5 phosphorylation, in particular, the type I receptors involved, is not known. 106 
Some studies have concluded that the canonical TGF- receptors TGFBR1 and 107 
TGFBR2 are sufficient for phosphorylation of both SMAD2/3 and SMAD1/5 (Liu et 108 
al., 2009, Wrighton et al., 2009). In contrast, others demonstrated that one of the 109 
classic BMP type I receptors (ACVR1 or BMPR1A), or in endothelial cells, 110 
ACVRL1, is additionally required (Daly et al., 2008, Goumans et al., 2002, Goumans 111 
et al., 2003). The second crucial issue concerns the biological relevance of TGF--112 
induced SMAD1/5 signaling. Nothing is known about the transcriptional program 113 
activated by this arm of TGF- signaling, or indeed, the specific SMAD complexes 114 
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involved. It is also not known to what extent this pathway is required for the 115 
physiological responses to TGF-. 116 
 Here we dissect the SMAD1/5 arm of TGF- signaling and define the 117 
underlying mechanism and its biological function. We show that TGF--induced 118 
SMAD1/5 phosphorylation requires both TGFBR1 and ACVR1 and using biosensors, 119 
and an optogenetic approach, we establish a new paradigm for TGF- receptor 120 
activation. We have mapped the binding sites on chromatin of nuclear phosphorylated 121 
SMAD1/5 (pSMAD1/5) genome-wide, which led us to define the target genes 122 
regulated by this arm of TGF- signaling. We go on to show that this arm of signaling 123 
is required for TGF--induced EMT. Our data reveal that the full transcriptional 124 
programme activated in response to TGF- requires integrated combinatorial 125 
signaling via both the SMAD2/3 and SMAD1/5 pathways.  126 
  127 
 6 
Results 128 
 129 
The kinetics of TGF--mediated SMAD1/5 phosphorylation  130 
To begin to dissect which receptors are required for TGF--induced SMAD1/5 131 
phosphorylation, we compared the kinetics of SMAD1/5 and SMAD2 132 
phosphorylation in response to TGF-. Using the human breast cancer cell line MDA-133 
MB-231 and the mouse mammary epithelial cell line NMuMG as model systems we 134 
found that TGF- induced only transient phosphorylation of SMAD1/5 that peaked at 135 
1 hr and then returned to baseline (Figure 1A). This was in contrast to a more 136 
sustained TGF--induced SMAD2 phosphorylation, or SMAD1/5 phosphorylation in 137 
response to BMP4. However, transient SMAD1/5 phosphorylation is not a defining 138 
characteristic of this arm of TGF- signaling, as another human breast cancer line, 139 
BT-549, exhibited sustained SMAD1/5 phosphorylation that is still readily detectable 140 
8 hr after TGF- stimulation (Figure 1 – figure supplement 1A). Furthermore, when 141 
BT-549 cells were grown as non-adherent spheres, TGF--induced SMAD1/5 142 
phosphorylation did not attenuate at all in the first 8 hr of signaling (Figure 1 – figure 143 
supplement 1A). Thus, the kinetics of TGF--induced SMAD1/5 phosphorylation is 144 
cell type-specific and dependent on the culture conditions and are independent of the 145 
kinetics of TGF--induced SMAD2/3 phosphorylation, suggesting a distinct receptor 146 
complex may be involved.  147 
 To address whether new protein synthesis was required for the transient nature 148 
of TGF--induced SMAD1/5 phosphorylation, cells were induced with TGF- in the 149 
presence of either a translation inhibitor, cycloheximide or a transcription inhibitor, 150 
actinomycin D. Inhibition of translation was uninformative because it also led to a 151 
very rapid loss of TGFBR2 and TGFBR1, due to their short half-lives (Vizan et al., 152 
2013). Use of actinomycin D, however, circumvented this problem, as TGFBR2 and 153 
TGFBR1 mRNAs are relatively stable (Figure 1 - figure supplement 1B) and their 154 
translation was unimpeded. In these conditions SMAD1/5 phosphorylation was 155 
sustained (Figure 1B; Figure 1 - figure supplement 1C). Thus, the rapid loss of 156 
pSMAD1/5 at later time points after TGF- stimulation requires new transcription, 157 
suggesting that it is mediated by a component whose expression is induced by TGF-.  158 
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Acute TGF- stimulation results in the rapid internalization of the receptors, 159 
which is sufficient to deplete almost all of the type II receptor TGFBR2 from the cell 160 
surface (Vizan et al., 2013). As a result, cells are refractory to further acute TGF- 161 
stimulation, read out by SMAD2 phosphorylation (Vizan et al., 2013). Cells in this 162 
refractory state were also unable to induce SMAD1/5 phosphorylation in response to 163 
TGF-, although they remained responsive to BMP4 (Figure 1C, Figure 1 - figure 164 
supplement 1D). This suggested that TGFBR2 is required for TGF--induced 165 
SMAD1/5 activation.  166 
 167 
TGF--induced SMAD1/5 phosphorylation requires the kinase activity of two 168 
different type I receptors 169 
The distinct kinetics of TGF--induced SMAD1/5 phosphorylation compared with 170 
SMAD2/3 phosphorylation suggested that different receptor complexes are likely 171 
involved. To explore this further, we used combinations of well-characterized small 172 
molecule inhibitors of the type I receptor kinases in MDA-MB-231 cells. SB-431542, 173 
a selective TGFBR1/ACVR1B/ACVR1C inhibitor (Inman et al., 2002), completely 174 
inhibited the phosphorylation of both SMAD1/5 and SMAD2 in response to TGF- 175 
when used at 10 µM (Figure 1D), indicating that the kinase activity of TGFBR1 is 176 
essential for TGF--induced SMAD1/5 phosphorylation. Interestingly, a 40-fold 177 
lower dose also substantially inhibited SMAD1/5 phosphorylation, whilst having less 178 
effect on SMAD2 phosphorylation (Figure 1D). TGF--induced SMAD1/5 179 
phosphorylation was also partially inhibited by the BMP type I receptor inhibitor 180 
LDN-193189 (Cuny et al., 2008) (Figure 1D), establishing a requirement for a 181 
member of this class of type I receptors. Strikingly, the combination of the low dose 182 
SB-431542 and LDN-193189 completely inhibited TGF--dependent SMAD1/5 183 
phosphorylation, without affecting phosphorylation of SMAD2 (Figure 1D). 184 
Analogous results were obtained in NMuMG cells (Figure 1 – figure supplement 1E). 185 
We conclude that the kinase activity of both classes of type I receptor is 186 
required for maximal SMAD1/5 phosphorylation downstream of TGF-. Taking these 187 
results together with the receptor expression profiles of these cells and receptor 188 
knockdown experiments (Daly et al., 2008), we deduce that the receptors involved are 189 
TGFBR1, a canonical BMP type I receptor (ACVR1 and/or BMPR1A) and TGFBR2. 190 
 191 
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SMAD1 is primarily phosphorylated by ACVR1 192 
We next used an in vitro approach to explore why TGF--induced phosphorylation of 193 
SMAD1 requires two different type I receptors. We focused on ACVR1 as a 194 
representative of the BMP type I receptor class, as it is the most homologous to 195 
ACVRL1 that responds to TGF- in endothelial cells (Chen and Massague, 1999). 196 
Moreover, in some cell types, knockdown of ACVR1 was sufficient to block TGF--197 
induced pSMAD1/5 (Daly et al., 2008). 198 
SMAD1 is known to be a poor substrate for TGFBR1 in vivo (Kretzschmar et 199 
al., 1997, Hoodless et al., 1996). We demonstrated that SMAD1 is also a poor 200 
substrate for TGFBR1 in vitro, although it is efficiently phosphorylated by both 201 
ACVR1 and BMPR1A as expected (Figure 1 – figure supplement 2A, B). As a 202 
control we showed that TGFBR1 could potently phosphorylate SMAD2, and 203 
surprisingly, ACVR1 was also able to phosphorylate SMAD2 (Figure 1 – figure 204 
supplement 2A, B).  205 
Given that SMAD1 is a poor substrate for TGFBR1, it is intriguing that the 206 
kinase activity of TGFBR1 is essential for TGF--induced SMAD1 phosphorylation. 207 
We hypothesized that TGFBR1 might catalyze a priming phosphorylation on 208 
SMAD1, which then serves as a substrate for ACVR1, or vice versa. To address this 209 
we mapped the sites phosphorylated by ACVR1 on full length SMAD1. We identified 210 
three species of C-terminal SMAD1 phosphorylation by ACVR1 – a dually 211 
phosphorylated S[pS]V[pS] and the singly phosphorylated [pS]SVS and S[pS]VS 212 
(Figure 1 – figure supplement 2C). From this it was clear that ACVR1 could 213 
phosphorylate both serines in the critical SVS motif and we deduced that the order of 214 
phosphorylation is the penultimate serine of the motif, followed by the terminal one. 215 
Moreover, if the preceding serine was phosphorylated, it prevented the 216 
phosphorylation of the other sites.  217 
Taking all these results together, we conclude that in response to TGF-, the 218 
receptor kinase that phosphorylates SMAD1 is ACVR1 and not TGFBR1, and it does 219 
so on both serines in the SVS motif in a defined order. 220 
  221 
ACVR1 is activated by TGFBR1 in vitro and in vivo 222 
The absence of a role for the TGFBR1 kinase activity in phosphorylating SMAD1 left 223 
open the question of why it is required in vivo for TGF--induced SMAD1/5 224 
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phosphorylation. We postulated that it might be necessary for ACVR1 activation, and 225 
therefore investigated whether TGFBR1 could directly phosphorylate ACVR1. Both 226 
TGFBR1 and ACVR1 exhibit significant autophosphorylation activity in vitro, which 227 
was inhibited by SB-505124 (DaCosta Byfield et al., 2004) and LDN-193189 228 
respectively (Figure 2A). Crucially, when TGFBR1 and ACVR1 were co-incubated, 229 
ACVR1 was phosphorylated, even in the presence of LDN-193189, indicating that 230 
ACVR1 is a substrate of TGFBR1 (Figure 2A). 231 
 To determine whether TGFBR1 could activate ACVR1 in vivo we used an 232 
optogenetic approach. To this end we fused the light-oxygen-voltage (LOV) domain 233 
of aureochrome1 from Vaucheria frigida, which dimerizes upon blue light stimulation 234 
(Sako et al., 2016), to the C-terminal ends of the intracellular domains of a 235 
constitutively-activated TGFBR1 (mutation T204D) (Wieser et al., 1995) and of wild 236 
type ACVR1, along with an N-terminal myristoylation motif to anchor them to the 237 
plasma membrane (Figure 2B; Supplementary Files 1 and 2). We refer to these 238 
constructs as Opto-TGFBR1* and Opto-ACVR1, respectively. We tested their ability, 239 
alone or in combination, to induce phosphorylation of SMAD1/5 in NIH-3T3 cells co-240 
transfected with FLAG-SMAD1 to increase the range of the assay. Transfection of the 241 
Opto-ACVR1 alone resulted in no phosphorylation of co-transfected FLAG-SMAD1, 242 
either in the absence or presence of blue light. However, when Opto-ACVR1 and 243 
Opto-TGFBR1* were co-transfected, a robust light-inducible phosphorylation of 244 
FLAG-SMAD1 was observed (Figure 2C). Importantly, this was inhibited by both 245 
SB-505124 and LDN-193189, confirming the involvement of both receptors (Figure 246 
2D). This directly demonstrates that TGFBR1 can activate ACVR1 in vivo. As a 247 
control, we showed that Opto-TGFBR1* phosphorylated co-expressed GFP-SMAD3 248 
in the presence of light, which was inhibited by SB-505124, but to a much lesser 249 
extent by LDN-193189 (Figure 2E). As a further control to ensure that the activation 250 
of ACVR1 by TGFBR1 required the kinase activity of the latter, we made a kinase-251 
dead version of Opto-TGFBR1. This construct was unable to induce the activity of 252 
ACVR1 in a light inducible manner and was also unable to induce phosphorylation of 253 
GFP-SMAD3 (Figure 2 – figure supplement 1).  254 
 To confirm that the light-inducible phosphorylation of FLAG-SMAD1 255 
observed with the combination of Opto-ACVR1 and Opto-TGFBR1* genuinely 256 
resulted from activation of Opto-ACVR1 by Opto-TGFBR1*, we generated a mutant 257 
version of Opto-ACVR1, in which the serines and threonines of the GS domain were 258 
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mutated to alanine and valine respectively. Since phosphorylation of these serines and 259 
threonines is required for type I receptor activation, we would expect this mutant to be 260 
uninducible (Wieser et al., 1995). Indeed, we found that light-inducible 261 
phosphorylation of FLAG-SMAD1 was inhibited when this GS domain mutant of 262 
Opto-ACVR1 was used instead of the wild type Opto-ACVR1 (Figure 2F, G).   263 
 We therefore conclude that the requirement of the kinase activity of both 264 
TGFBR1 and ACVR1 for TGF--induced phosphorylation of SMAD1/5 reflects a 265 
requirement for activation of ACVR1 by TGFBR1 through phosphorylation of the 266 
ACVR1 GS domain. 267 
 268 
TGF- leads to clustering of ACVR1 and TGFBR1  269 
Having shown that both type I receptors are required, we next tested whether they 270 
were components of the same tetrameric receptor complex, or whether they resided in 271 
separate receptor complexes that clustered at the cell membrane in response to ligand 272 
stimulation (compare model I and model II, Figure 3A). To distinguish between these 273 
possibilities we used previously published recombinant versions of TGF-3, 274 
designated WW and WD (Huang et al., 2011). TGF-3WW, the wildtype TGF-3 275 
dimer, is composed of two identical monomeric TGF-3 subunits, whereas TGF-276 3WD contains one wildtype subunit of TGF-3 and one mutated subunit that cannot 277 
bind to either TGFBR2 or TGFBR1 (Huang et al., 2011). Thus, while the TGF-3WW 278 
ligand engages two type II:type I pairs in the tetrameric complex, the TGF-3WD 279 
ligand can only engage one pair. In addition, TGF-3WW does not bind ACVR1, and 280 
by inference, neither does TGF-3WD (data not shown). It was previously 281 
demonstrated that TGF-3WD binding to a single type II:type I receptor pair is 282 
sufficient to induce phosphorylation of SMAD3 (Huang et al., 2011). We therefore 283 
reasoned that if model I was correct then only TGF-3WW would induce 284 
phosphorylation of SMAD1/5, as the heterotetrameric complex would not be able to 285 
be assembled with TGF-3WD. If model II was correct, however, then both TGF-286 3WW and TGF-3WD would be competent to induce pSMAD1/5. Treatment of MDA-287 
MB-231 or NMuMG cells with either TGF-3WW or TGF-3WD led to a dose-288 
dependent increase in both SMAD1 and SMAD2 phosphorylation (Figure 3B; Figure 289 
3 – figure supplement 1). Thus, TGF- stimulation is unlikely to lead to formation of 290 
a heterotetrameric complex comprising TGFBR2/TGFBR1/ACVR1, but instead, 291 
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leads to the formation of a higher order receptor cluster at the cell surface that 292 
includes TGFBR2/TGFBR1 complexes and ACVR1. 293 
 294 
TGF- induces ACVR1 activation in vivo in a TGFBR1-dependent manner 295 
To obtain direct evidence that TGF- activates ACVR1, we generated an ACVR1 296 
biosensor that fluoresces when activated. In this construct ACVR1 is fused to the 297 
conformation-sensitive circularly permutated yellow fluorescent protein (cpYFP) core 298 
of the InversePericam Ca2+ sensor and FKBP1A (formerly FKBP12) to make 299 
ACVR1-InversePericam-FKBP1A (ACVR1-IPF) (Michel et al., 2011). When the 300 
receptor is inactive, the FKBP1A moiety binds to the GS domain of the receptor, 301 
which suppresses cpYFP fluorescence. Upon ligand induction, phosphorylation of the 302 
GS domain releases FKBP1A, allowing the cpYFP to adopt a fluorescent 303 
conformation (Michel et al., 2011). We first showed that ACVR1-IPF is functional in 304 
that it is able to induce phosphorylation of SMAD1/5 when overexpressed (Figure 4 – 305 
figure supplement 1A). We then stably expressed this biosensor in a number of cell 306 
lines (Figure 4 – figure supplement 1B). In the polarized epithelial cell line, MDCKII 307 
and in NIH-3T3 fibroblasts, ACVR1-IPF is readily detectable at the cell membrane, 308 
as well as in internal structures, and had no adverse effect on the inducibility of these 309 
cells in response to TGF- or BMP4 (Figure 4 – figure supplement 1B–D). As a 310 
control we showed that ACVR1-IPF was activated in response to FK506 which binds 311 
FKBP1A and releases it from the GS domain of ACVR1 (Wang et al., 1994) (Figure 312 
4 – figure supplement 1E). Treatment of the MDCKII ACVR1-IPF cells with TGF- 313 
resulted in a significant increase in fluorescence that was inhibited by SB-431542 314 
(Figure 4A and B; Videos 1–3). Furthermore, using flow cytometry for a more 315 
quantitative approach we demonstrated that the TGF--induced increase in 316 
fluorescence was blocked by both SB-431542 and a TGF- neutralizing antibody and 317 
was independent of BMP signaling, as it was unaffected by the BMP antagonist 318 
Noggin (Figure 4C). Similarly, TGF- also activated ACVR1 in NIH-3T3 ACVR1-319 
IPF cells in a TGFBR1-dependent manner (Figure 4 – figure supplement 1F, G; 320 
Videos 4–6).  321 
 322 
Mapping the binding sites on chromatin for TGF--induced pSMAD1/5 reveals 323 
that ID genes are major transcriptional targets of this pathway 324 
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Although the existence of TGF--induced pSMAD1/5 has been known for some time, 325 
its transcriptional role has never been addressed. Earlier experiments had suggested 326 
that TGF--induced pSMAD1/5 could only be found in complex with pSMAD2/3 327 
(Daly et al., 2008), but using optimized immunoprecipitation conditions it was clear 328 
that TGF--induced pSMAD1/5 can also be part of pSMAD1/5–SMAD4 complexes 329 
(Figure 5A). We therefore used chromatin immunoprecipitation sequencing (ChIP-330 
seq) for pSMAD1/5 to explore where in the genome pSMAD1/5 binds in response to 331 
TGF-. We also wanted to determine  which SMAD complexes were primarily 332 
responsible for regulating transcription in addition to the canonical pSMAD2/3–333 
SMAD4 complexes (Figure 5A).  334 
 ChIP-seq in MDA-MB-231 cells for pSMAD1/5 and SMAD3 (as a control) 335 
resulted in 2378 pSMAD1/5 peaks and 2440 SMAD3 peaks identified in response to 336 
TGF- after filtering (Figure 5 - Source data 1, sheet 1). The majority of the 337 
pSMAD1/5 peaks (2287) were also bound by SMAD3. To identify binding sites 338 
preferentially bound by pSMAD1/5 versus SMAD3 we calculated the ratio of the 339 
number of tags in the pSMAD1/5 peaks versus the SMAD3 peaks, and focused on the 340 
100 peaks with the highest pSMAD1/5:SMAD3 tag ratio (Figure 5 - Source data 1, 341 
sheet 2). Interrogating the nearest genes to these peaks we found a significant 342 
enrichment of both TGF- and BMP target genes (Figure 5 - Source data 1, sheets 2 343 
and 3). Strikingly, 8 of the top 10 peaks flanked known BMP target genes (ID1, ID3, 344 
ID4, ATOH8, BIRC3) (Figure 5B; Figure 5 – figure supplement 1A; Figure 5 - Source 345 
data 1, sheet 2) (Gronroos et al., 2012). In contrast, classical TGF- target genes like 346 
JUNB, BHLHE40, PMEPA1, SERPINE1 (Levy and Hill, 2005) were not in this top 347 
100 list, but were amongst those with the highest enrichment for SMAD3 (Figure 5B; 348 
Figure 5 – figure supplement 1A; Figure 5 - Source data 1, sheet 1). Using ChIP-349 
qPCR, we validated these different binding patterns (Figure 5C; Figure 5 – figure 350 
supplement 1A). For pSMAD1/5, the binding in response to TGF- was transient, 351 
peaking at 1 hr and thereafter decreasing, whilst SMAD3 binding at JUNB and 352 
PMEPA1 was sustained. A subset of the peaks were also validated in BT-549 cells 353 
(Figure 5 – figure supplement 1B).  354 
We performed motif enrichment analyses on the top 50 and 100 peaks with the 355 
highest pSMAD1/5:SMAD3 tag ratio. In both cases a SMAD1/5 binding motif 356 
GGCGCC was found (Figure 5D and E; Figure 5 – figure supplement 1C) 357 
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(Gaarenstroom and Hill, 2014). In addition, in the top 50 peaks the composite 358 
SMAD1/5–SMAD4 site was clearly identified (GGCGCC(N5)GTCT) (Gaarenstroom 359 
and Hill, 2014, Morikawa et al., 2011) (Figure 5 – figure supplement 1C), with a 360 
slightly more degenerate version being present in the top 100 peaks (Figure 5D). This 361 
strongly suggests that TGF--induced SMAD1/5–SMAD4 complexes are responsible 362 
for regulating the genes with the highest enrichment of pSMAD1/5. 363 
The enrichment of pSMAD1/5 on the ID genes in response to TGF- suggests 364 
that they are bona fide target genes of this arm of TGF- signaling. We confirmed this 365 
using siRNAs to deplete specific SMADs. TGF- induction of ID1 and ID3 in MDA-366 
MB-231 cells depended on SMAD1/5 and SMAD4, but not SMAD3 (Figure 5 – 367 
figure supplement 2A and B). In contrast, the induction of JUNB required SMAD3 368 
and SMAD4, but was independent of SMAD1/5 (Figure 5 – figure supplement 2A 369 
and B). We further corroborated these observations using the drug dosing strategy that 370 
selectively inhibits SMAD1/5 phosphorylation in response to TGF- (Figure 1D). The 371 
combination of low dose SB-431542 and LDN-193189 greatly decreased ID gene 372 
induction without impacting on the induction of JUNB in both MDA-MB-231 and 373 
NMuMG cells (Figure 5 – figure supplement 2C and D). The induction of target gene 374 
expression was also examined after treatment of cells with TGF-3WW or TGF-3WD. 375 
As expected both TGF- ligands induced the expression of the IDs and JUNB (Figure 376 
5 – figure supplement 2E).  377 
The results in this section reveal that pSMAD1/5–SMAD4 complexes formed 378 
in response to TGF- are responsible for regulating the genes with the highest 379 
enrichment of pSMAD1/5, and that the IDs are major early downstream targets. 380 
 381 
The SMAD1/5 arm of TGF- signalling is required for TGF--induced EMT  382 
The ID proteins have been implicated in many processes involved in oncogenesis 383 
(Lasorella et al., 2014), and importantly, ID1 was shown to be upregulated by TGF- 384 
in tumor cells isolated from pathological pleural fluids from patients with ER- and 385 
ER+ metastatic breast cancer, and also in patient-derived glioblastomas (Anido et al., 386 
2010, Padua et al., 2008). Since we have now shown that the pSMAD1/5 arm of TGF-387  signaling is responsible for TGF--induced ID1 induction, this prompted us to 388 
explore further the biological relevance of the pSMAD1/5 arm of TGF- signaling in 389 
oncogenic processes, and to gain a comprehensive view on the relative contribution of 390 
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this arm of signaling to longer term TGF- responses. We decided to focus on the 391 
process of EMT, as this is a key step in tumorigenesis that confers a migratory 392 
phenotype, acquisition of stem cell properties and resistance to chemotherapeutic 393 
agents (Ye and Weinberg, 2015). For these studies we primarily used the NMuMG 394 
cell model, as we have shown above that these cells show a robust phosphorylation of 395 
SMAD1/5 in response to TGF- and are well known to undergo a TGF--induced 396 
EMT within 48 hr (Piek et al., 1999).  397 
 CRISPR/Cas9 was used to generate clones of NMuMG cells deleted for 398 
SMAD1 and SMAD5 (Figure 6A; Figure 6 – figure supplement 1A–C). We compared 399 
the TGF--induced transcriptome at 48 hr of the parental clone with one deleted for 400 
SMAD1/5 using RNA-sequencing (RNA-seq). Of the 5798 genes that are 401 
significantly up- or down-regulated by TGF- in this time frame we found that 402 
approximately a quarter (1398) were dependent on the SMAD1/5 branch of signaling 403 
(see Materials and Methods for the cut-offs used) (Figure 6 - Source data 1, sheets 1 404 
and 2). This demonstrates that this arm of TGF- signaling plays a crucial role in long 405 
term downstream transcription responses. To corroborate the RNA-seq results we 406 
validated a subset of them by qPCR, measuring levels of mRNA over time in 407 
response to TGF-  (Figure 6 – figure supplement 2).  408 
 Gene set enrichment analysis revealed that the TGF- target genes that depend 409 
on this arm of signaling were involved in processes such as regulation of the 410 
cytoskeleton, focal adhesions, adherens and tight junctions, as well as TGF- 411 
signaling in EMT (Figure 6 - Source data 1, sheet 3). We therefore next investigated 412 
whether TGF--induced EMT required SMAD1/5 signaling. Using delocalization of 413 
the adherens junction marker CDH1 (also called E-Cadherin) together with loss of the 414 
tight junction marker TJP1 (also called ZO-1) as a measure of EMT, we could readily 415 
demonstrate that signaling through SMAD1/5 was crucial for this process in two 416 
separate ΔSMAD1/5 clones (Figure 6B; Figure 6 – figure supplement 1D). In 417 
addition, we observed that two mesenchymal markers, Acta2 (also called smooth 418 
muscle actin) and Fn1 were more weakly induced in the ΔSMAD1/5 clone compared 419 
with the wild type (Figure 6 – figure supplement 2). We also used an siRNA 420 
knockdown approach, and showed that EMT was dependent on SMAD1/5, SMAD4 421 
and SMAD3, but independent of SMAD2 (Figure 6 – figure supplement 3A and B ). 422 
Furthermore, treatment of the cells with the BMP type 1 receptor inhibitor, LDN-423 
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193189 also inhibited EMT either alone or when combined with low dose SB-431542 424 
which we have shown is sufficient to inhibit TGF--induced SMAD1/5 signaling, but 425 
not signaling through SMAD2/3 (Figure 6C and D; Figure 6 – figure supplement 3C). 426 
Moreover DMH1, another BMP type 1 receptor inhibitor, had a similar effect (Figure 427 
6 – figure supplement 3C and D). Finally, to confirm that that the dependence of 428 
TGF- induced EMT on SMAD1/5 signaling was not unique to NMuMG cells, we 429 
used another mouse mammary cell line, EpRas that also undergoes a TGF--induced 430 
EMT (Daly et al., 2010, Grunert et al., 2003). SMAD1/5 signaling in this line was 431 
also essential for EMT (Figure 6E and F).  Thus, we conclude that TGF--induced 432 
EMT requires the SMAD1/5 arm of the signaling pathway, as well as the canonical 433 
pathway through SMAD3.  434 
Taking our ChIP-seq and RNA-seq analyses together, we found that the ID 435 
genes are major early transcriptional targets of the SMAD1/5 arm of the TGF- 436 
pathway. Of these, ID1 was the prominent family member up regulated by TGF- in 437 
NMuMGs (Figure 7 – figure supplement 1A). We hypothesized that the dependency 438 
on the SMAD1/5 arm of the TGF- pathway could reflect a requirement of ID1 for 439 
EMT. We tested this by knocking down Id1 with siRNAs, both as a pool and as 440 
individual siRNAs and found that cells depleted of ID1 were indeed unable to 441 
undergo TGF--induced EMT (Figure 7A and B; Figure 7 figure supplement 1B and 442 
C). Thus, we conclude that TGF--induced up-regulation of ID1 is essential for EMT. 443 
  444 
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Discussion 445 
 446 
Combinatorial signaling downstream of TGF- 447 
Here we have defined both the mechanism whereby TGF- induces the 448 
phosphorylation of SMAD1/5, and its functional role. We have shown that two type I 449 
receptors are required, the canonical TGF- receptor TGFBR1, and additionally, one 450 
of the classical BMP type I receptors, ACVR1. Using in vitro kinase assays, an 451 
optogenetic approach and an ACVR1 receptor fluorescent biosensor, we have 452 
uncovered a new mechanism for receptor activation whereby one type I receptor 453 
activates another. We show that in response to TGF-, TGFBRI phosphorylates and 454 
activates ACVR1, which phosphorylates SMAD1/5. To address the functional 455 
significance of this arm of TGF- signaling we used genome-wide ChIP-seq and 456 
RNA-seq and show that approximately a quarter of the TGF--regulated 457 
transcriptome is dependent on SMAD1/5, with major early targets being the ID 458 
transcriptional regulators. Finally, we have also demonstrated that the SMAD1/5 459 
pathway is essential for TGF--induced EMT, and this reflects a requirement for ID1.  460 
 Taking these results together with previous work (Liu et al., 2009, Daly et al., 461 
2008) we propose a model of combinatorial signaling that is essential for the TGF- 462 
cellular program (Figure 7C). In most cells tested the induction of pSMAD1/5 is more 463 
transient than the pSMAD2/3 induction (Liu et al., 2009, Daly et al., 2008). Thus, the 464 
initial transcriptional program is regulated by both SMAD pathways and is refined at 465 
later time points by the SMAD2/3 pathway. Therefore, the full TGF--induced 466 
transcriptional program requires combinatorial signaling via both SMAD pathways. 467 
With respect to the functional relevance of TGF--induced SMAD1/5 468 
phosphorylation, we have now shown that complete EMT requires both SMAD 469 
pathways. TGF--induced anchorage-independent growth, migration and invasion 470 
have also been shown to require SMAD1/5 signaling, whilst TGF--induced growth 471 
arrest is only dependent on SMAD2/3 signaling (Liu et al., 2009, Daly et al., 2008) 472 
(Figure 7C).  473 
 Since we have now demonstrated that TGF- induces the formation of 474 
SMAD1/5–SMAD4 complexes that regulate canonical BMP target genes, it is 475 
important to ask what discriminates TGF- signaling from BMP signaling as it is well 476 
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known that BMP and TGF- functional responses are distinct (Itoh et al., 2014, 477 
Miyazono et al., 2010). The answer lies in the combinatorial signaling, and likely also 478 
in the signaling dynamics. In contrast to TGF-, BMP stimulation leads to a sustained 479 
phosphorylation of SMAD1/5 in the absence of SMAD2/3 activation (Gronroos et al., 480 
2012, Daly et al., 2008). As a result, although the gene expression program 481 
downstream of BMP shares some common targets with that downstream of TGF- at 482 
early time points, it will be completely distinct at later time points as a result of the 483 
sustained SMAD1/5 signaling and the absence of SMAD2/3-driven transcription 484 
(Figure 7C). 485 
 486 
Receptor requirements for TGF--induced SMAD1/5 phosphorylation 487 
We have shown that two classes of type I receptors are necessary for TGF--induced 488 
SMAD1/5 phosphorylation, the canonical TGF- receptor, TGFBR1 and one of the 489 
BMP type I receptors, of which we have focused on ACVR1. Our results demonstrate 490 
that the kinase activity of TGFBR1 is essential for activation of ACVR1, whereas the 491 
kinase activity of ACVR1 is necessary to phosphorylate SMAD1/5. Surprisingly, we 492 
found that inhibition of TGF--induced SMAD1/5 phosphorylation by LDN-193189, 493 
which inhibits the BMP type I receptors, is incomplete, even though the same LDN-494 
193189 concentration is sufficient to inhibit BMP-induced SMAD1/5 495 
phosphorylation. This same result was also previously seen when the BMP type I 496 
receptor inhibitor dorsomorphin was used (Daly et al., 2008). A complete inhibition 497 
of TGF--induced pSMAD1/5 is achieved by combining LDN-193189 with a sub-498 
optimal dose of SB-431542. This is likely explained by the fact that LDN-193189-499 
inhibited ACVR1 is still able to efficiently recruit SMAD1/5, where it may be 500 
inefficiently phosphorylated by TGFBR1, which is sensitive to the sub-optimal dose 501 
of SB-431542. The requirement for two distinct type I receptors fits well with what 502 
was shown for TGF- responses in endothelial cells, where ACVLR1 and TGFBR1 503 
were both required (Goumans et al., 2003, Goumans et al., 2002).  504 
 Our optogenetic experiments revealed that activated TGFBR1 phosphorylates 505 
and activates ACVR1 in vivo.  We previously hypothesized that TGFBR1 and 506 
ACVR1 could be in the same receptor complex (Daly et al., 2008), but  our use of the 507 
mutant TGF-3 ligands here indicated that these two type I receptors are not part of 508 
an obligate heterotetrameric receptor, but rather that TGFBR1, activated by TGFBR2 509 
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as a result of TGF- stimulation can phosphorylate and activate ACVR1 in the 510 
membrane as a result of receptor clustering (Figure 7C). We were surprised to see in 511 
our optogenetic experiments that light-induced dimers of the activated kinase domain 512 
of TGFBR1 were much more active than the monomeric domains, as this suggests 513 
that TGFBR1 is able to autophosphorylate and auto-activate in the absence of type II 514 
receptors, if brought into close proximity. In fact, a similar observation was made in 515 
early studies using chimeric receptors with the extracellular domain of the 516 
erythropoietin receptor and the intracellular domain of constitutively active TGFBR1 517 
(Luo and Lodish, 1996). This chimeric receptor could only mediate a growth arrest 518 
after stimulation with erythropoietin, indicating that clustering was important for 519 
receptor activity in vivo.  520 
 521 
Dynamics of TGF--induced pSMAD1/5 signaling 522 
We and others have observed that in most cell types TGF--induced SMAD1/5 523 
phosphorylation is transient compared with SMAD2/3 phosphorylation (Daly et al., 524 
2008, Liu et al., 2009, Wrighton et al., 2009). Using pSMAD2 as a readout, we 525 
previously showed that pSMAD2 levels attenuate over time, and remain at a low 526 
steady state level that depends on receptors replenishing the cell surface, for as long 527 
as ligand is available (Vizan et al., 2013). Our demonstration that levels of 528 
fluorescence of the ACVR1-IPF biosensor steadily increase over a number of hours 529 
indicates that ACVR1 can also be continuously activated for as long as ligand is 530 
present. We have shown that the transience of SMAD1/5 phosphorylation requires 531 
new protein synthesis, indicating that SMAD1/5 phosphorylation is likely to be 532 
actively terminated by an inhibitor induced by the pathway. Given the prolonged 533 
activation of ACVR1-IPF in response to ligand, we hypothesize that such an inhibitor 534 
is unlikely to target the receptors, but might be a TGF--induced phosphatase that 535 
targets phosphorylated SMAD1/5 directly. The transience of SMAD1/5 536 
phosphorylation is not a defining characteristic of this arm of TGF- signaling as BT-537 
549 breast cancer cells exhibit a more sustained response, which is even more 538 
pronounced when the cells are grown as spheres. Comparing TGF- target genes in 539 
BT-549s versus MDA-MB-231s where the response is transient, might shed light on 540 
the identity of the putative inhibitor. 541 
 542 
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TGF--induced pSMAD1/5 is transcriptionally active and required for a subset 543 
of TGF--induced target genes 544 
Our ChIP-seq analysis demonstrated for the first time that TGF--induced 545 
pSMAD1/5 accumulates in the nucleus and binds to chromatin. These experiments 546 
revealed that the peaks with the highest pSMAD1/5 enrichment flanked classical 547 
BMP target genes, such as ID1, ID3 and ATOH8. Analysis of the binding sites led us 548 
to the discovery that the SMAD complexes responsible for inducing these target 549 
genes downstream of TGF- were pSMAD1/5–SMAD4 complexes. The ChIP-seq 550 
analysis also revealed widespread co-binding of pSMAD1/5 and SMAD3, which was 551 
surprising. For the classical BMP targets, the ratio of pSMAD1/5:SMAD3 in the 552 
peaks was high, whereas at classical TGF- targets like JUNB, PMEPA1, SERPINE1 553 
and BHLHE40 (Kang et al., 2003, Levy and Hill, 2005), this ratio was less than 1. We 554 
do not fully understand the functional significance of the pSMAD1/5 and SMAD3 co-555 
binding. We previously demonstrated that at least in some contexts, pSMAD3–556 
pSMAD1/5 complexes are inhibitory (Gronroos et al., 2012), and this is evident in the 557 
work presented here for ID3 induction. However, for JUNB we found that knockdown 558 
of SMAD1/5 had no effect on TGF--induced transcription, suggesting that 559 
pSMAD1/5 is not contributing to its transcriptional regulation. This may also be true 560 
of other genes with a similar pattern of SMAD3/pSMAD1/5 binding.  561 
 562 
TGF--induced SMAD1/5 signaling is required for EMT through induction of 563 
ID1. 564 
We have now shown that SMAD1/5 signaling in response to TGF- is required for a 565 
complete TGF--induced EMT in NMuMG cells and in EpRas cells. This accounts 566 
for a previously unexplained observation that overexpression of dominant negative 567 
ACVR1 in NMuMGs caused a partial loss of EMT in response to TGF- (Miettinen 568 
et al., 1994). In an earlier study using siRNAs we had concluded that the SMAD1/5 569 
arm of the TGF- pathway was not required for EMT in EpRas cells (Daly et al., 570 
2008). The likely explanation for this discepency is the poor SMAD1/5 knockdown 571 
we achieved in those cells compared with the very effective strategy of inhibiting this 572 
arm of TGF- signaling using the combined small molecule inhibitors that we have 573 
employed here.  574 
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We have gone on to show that TGF--induced ID1 is required for EMT. 575 
Importantly, although ID1 is necessary for EMT, it is clearly not sufficient, as BMP 576 
cannot induce EMT in NMuMGs (Kowanetz et al., 2004). Consistent with this we 577 
have also shown that the SMAD3 pathway is essential for EMT. This arm of the 578 
pathway is likely required for the induction of some or all of the so-called EMT-579 
associated transcription factors, most notably SNAI1, SNAI2, ZEB1, ZEB2 and 580 
BHLH proteins such as TWIST1 and E47 (now called TCF3), some of which are 581 
known direct TGF- targets (Peinado et al., 2007, Diepenbruck and Christofori, 582 
2016).  583 
 Our finding that EMT depends on TGF--induced ID1 expression has 584 
implications for the role of SMAD1/5 and the IDs in cancer. The prevailing view is 585 
that ID1 is downregulated by TGF- in non-tumorigenic human epithelial lines, but 586 
upregulated by TGF- in established tumor cell lines, as we have observed here in 587 
MDA-MB231 and BT-549s, and also in patient-derived tumor cells (Anido et al., 588 
2010, Padua et al., 2008, Lasorella et al., 2014). Furthermore, ID proteins are 589 
overexpressed in many different tumor types, and are implicated in the maintenance 590 
of tumor stem cells and for some cancer-related phenotypes (Lasorella et al., 2014). 591 
ID1 was also found in a lung metastatic gene signature of breast cancer (Minn et al., 592 
2005). The role of ID1 in EMT is context dependent. In a recent study of breast 593 
cancer, ID1 was shown to be expressed in tumor cells that had already undergone an 594 
EMT, and it contributed to the growth of the primary tumor by inducing a stem cell-595 
like phenotype. At the metastatic site however, TGF--induced ID1 was proposed to 596 
induce an mesenchymal-to-epithelial transition (MET) by interferring with the 597 
activity of TWIST (Stankic et al., 2013). In light of our current data it will be 598 
important to investigate in what tumor contexts ID1 is required for EMT, and more 599 
broadly how the TGF-–SMAD1/5 pathway contributes to different aspects of 600 
tumorigenesis. 601 
  602 
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Materials and Methods 603 
 604 
Cell line origin, authentication and maintenance 605 
MDA-MB-231 cells were obtained from the ECACC/HPA culture collection, BT-549 606 
cells were obtained from the Francis Crick Institute Cell Services, NMuMG cells 607 
were obtained from ATCC,  MDCKII cells were obtained from Sigma, NIH-3T3 cells 608 
were obtained from Richard Treisman (Francis Crick Institute) and EpRas cells were 609 
obtained from Martin Oft and Hartmut Beug (IMP, Vienna). All cell lines have been 610 
banked by the Francis Crick Institute Cell Services, and certified negative for 611 
mycoplasma. In addition, MDA-MB-231 and BT-549 cells were authenticated using 612 
the short tandem repeat profiling, while MDCKII, NIH-3T3 and EpRas cells had 613 
species confirmation at the Francis Crick Institute Cell Services. Their identity was 614 
also authenticated by confirming that their responses to ligands and their phenotype 615 
were consistent with published history.  616 
MDA-MB-231, BT-549, EpRas, NIH-3T3 and MDCKII cells were maintained 617 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf 618 
serum (FCS) and 1% penicillin/streptomycin. NMuMG cells were grown in the same 619 
medium, but supplemented with 10 µg/ml insulin. MDA-MB-231 and MDCKII cells 620 
were starved overnight in OptiMEM prior to ligand stimulation; NMuMG cells were 621 
starved overnight in OptiMEM with 10 µg/ml insulin; NIH-3T3 cells were starved in 622 
DMEM with 0.5% FCS. For ligand stimulation experiments, BT-549 cells were 623 
plated in the mammosphere culture media (Dontu et al., 2003) (MEBM (PromoCell) 624 
with B27 (Thermo Fisher), 20 ng/ml EGF (PeproTech), 20 ng/ml bFGF (PeproTech) 625 
and 4 μg/ml heparin (Sigma)).  626 
 627 
Ligands and chemicals 628 
All recombinant ligands were reconstituted in 4.4 mM HCl supplemented with 0.1% 629 
BSA. Cells were treated with recombinant TGF-1 (PeproTech, 100-21C; 2 ng/ml), 630 
BMP4 (PeproTech, 120-05ET; 20 ng/ml) and Noggin (PeproTech, 250-38; 300 631 
ng/ml). TGF-3WW and TGF-3WD were as described (Huang et al., 2011). SB-632 
431542 (Tocris) was used at the concentrations indicated, SB-505124 (Tocris) at 10 633 
or 50 µM, LDN-193189 (a gift from Paul Yu) at 1 or 0.5 µM, DMH1 (Selleck 634 
Chemicals) at 1 µM, cyclohexamide (Sigma) at 20 µg/ml and actinomycin D (Sigma) 635 
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at 1 µg/ml. For TGF- blocking experiments, the pan-TGF- blocking antibody 636 
(1D11) and the control antibody (13C4) were used at 30 µg/ml (Nam et al., 2008). 637 
 638 
CRISPR/Cas9 knockout of SMAD1/5 and ACVR1/BMPR1A in NMuMG cells 639 
From the wildtype NMuMG cells, a parental clone was selected that expressed robust 640 
junctional markers (TJP1 and CDH1) and underwent an efficient EMT in response to 641 
TGF-. Two guide RNAs (see Key Resources Table) targeting the MH1 domain 642 
(SMAD1) and MH2 domain (SMAD5) were expressed from the plasmid 643 
pSpCas9(BB)-2A-GFP (PX458) (Ran et al., 2013) and used to knockout SMAD1 and 644 
SMAD5. NMuMG parental clone cells were simultaneously transfected with both 645 
plasmids, sorted for GFP expression, plated as single cells in 96-well plates and 646 
screened by sequencing to verify mutations in SMAD1 and SMAD5. Two knockout 647 
clones, SMAD1/5 clone 1 and 2, were used in these studies. The same parental clone 648 
of NMuMG cells was also used to generate a line knocked out for ACVR1 and 649 
BMPR1A. The strategy was as described for the SMAD1/5 knockout and the guides 650 
are given in the Key Resources Table. 651 
 652 
Generation of cell lines stably expressing ACVR1-IPF 653 
The inverse pericam FKBP1A (IPF) fusion protein was amplified by PCR from the 654 
pCS2+zALK3-IPF (Michel et al., 2011) and cloned in-frame downstream of the 655 
human ACVR1 cDNA sequence in the pcDNA3.1 Hygro + vector (Thermo Fisher). 656 
MDCKII and NIH-3T3 cells were transfected with the ACVR1-IPF construct and 657 
selected with 400 µg/ml hygromycin or 40 µg/ml hygromycin respectively. After 658 
selection, cells were FACS sorted for GFP expression. MDCKII ACVR1-IPF cells 659 
were maintained as a pool, while a single clone was isolated for NIH-3T3 cells. To 660 
test the functionality of ACVR1-IPF, NMuMG cells knocked out for ACVR1 and 661 
BMPR1A were transfected with empty pcDNA3.1 Hygro (+), ACVR1-IPF or FLAG-662 
ACVR1 (Daly et al., 2008) as a positive control, and activity was monitored by their 663 
ability to induce phosphorylation of SMAD1/5.  664 
 665 
Generation and LED light photoactivation of Opto-receptors 666 
 The general design of the Opto receptors was a previously described (Sako et al., 667 
2016). Opto-TGFBR1* and Opto-ACVR1 were generated by overlapping PCR 668 
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(Horton et al., 1990) to include a N-terminal myristyolation domain, the intracellular 669 
domain of either human TGFBR1 (residues 149-503) or human ACVR1 (residues 670 
147-509), a light-oxygen-voltage (LOV) domain from Vaucheria frigida (Takahashi 671 
et al., 2007) and a C-terminal HA-tag and cloned into the pCS2 expression plasmid 672 
(see Supplementary Files 1 and 2). In the case of TGFBR1, the T204D point mutation 673 
was introduced that renders the kinase constitutively active (Wieser et al., 1995), thus 674 
generating the construct Opto-TGFBR1*. A kinase dead version of Opto-TGFBR1 675 
was also generated in which K232 was mutated to R (Wrana et al., 1994). 676 
Furthermore, the GS-domain of ACVR1 (189TSGSGS194) was mutated to VAGAGA 677 
to generate Opto-ACVR1 GS-mut. NIH-3T3 cells were transfected with a total of 2 678 g of plasmid DNA that included either 5 ng of GFP-SMAD3 (Nicolas et al., 2004) 679 
or 25 ng of Flag-SMAD1 (Lechleider et al., 2001) alone or in combination with 25 ng 680 
of Opto-TGFBR1* and/or 50 ng of Opto-ACVR1 (WT or GS-mut). We co-681 
transfected the SMADs with the Opto-receptors to increase the range of the assay. 682 
Twenty-four hours post transfection, cells were starved overnight in DMEM with 683 
0.5% FCS. Cells were then left untreated or pre-treated with 0.5 M LDN-193189 or 684 
50 M SB-505124 and then exposed to blue light from an LED array for 1 hr at 37oC 685 
in a humidified incubator. Control cells (i.e. in the dark) were wrapped in aluminium 686 
foil and placed in the same incubator. 687 
 688 
siRNAs and transfections 689 
All siRNAs were purchased from Dharmacon/GE Health Care Life Sciences and are 690 
listed in Supplementary file 3. MDA-MB-231 and NMuMG cells were transfected 691 
with siRNAs at a final concentration of 20 nM with Interferin (Polyplus). Twenty four 692 
hours post transfection, cells were starved overnight, and the following day cells were 693 
treated with TGF- or BMP-4 for 1 hr and RNA and/or protein extracted. NMuMG 694 
cells were also treated with TGF- for a further 24–48 hr to assess the effects of target 695 
gene knockdown on EMT.  696 
 697 
EMT assay 698 
 699 
NMuMG or EpRas cells were plated on glass coverslips in 6-well plates (200,000 or 700 
75,000 cells respectively). For NMuMG cells treated with small molecule inhibitors, 701 
the media was changed the day after plating to OptiMEM with 10 µg/ml insulin and 702 
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the cells treated with 2 ng/ml TGF-alone or in combination with 0.125 µM SB-703 
431542, 1 µM LDN-193189 or DMH1 for the durations indicated. For knockdown 704 
experiments, NMuMG cells were transfected the day after plating with the indicated 705 
siRNAs. Twenty-four hours after transfection, the media was changed to OptiMEM 706 
with 10  µg/ml insulin and the following day, cells were treated with TGF- for the 707 
durations indicated. For EpRas, cells were treated with 2 ng/ml TGF-alone or in 708 
combination with 0.125 µM SB-431542 and 1 µM LDN-193189 the day after plating. 709 
EpRas cells were then split and re-plated at the initial splitting density in the presence 710 
of   2 ng/ml TGF-alone or in combination with SB-431542 and LDN-193189 every 711 
three days. 712 
 713 
Antibodies, immunoblotting, immunoprecipitations and indirect 714 
immunofluorescence  715 
All primary and secondary antibodies used are listed in the Key Resources Table. 716 
Western blots using whole cell extracts and immunoprecipitations followed by 717 
Western blotting were as previously described (Germain et al., 2000, Daly et al., 718 
2008). Indirect immunofluorescence of the ACVR1-IPF was performed after fixing 719 
cells in 4% formaldehyde for 5 minutes. Indirect immunofluorescence for CDH1 and 720 
TJP1 was performed after fixation in methanol:acetone (1:1) as previously described 721 
(Nicolas and Hill, 2003). Nuclei were counter stained with DAPI (0.1 µg/ml). 722 
Imaging was performed on a Zeiss Upright 780 confocal microscope. Z-stacks were 723 
acquired for all channels and maximum intensity projection images are shown. 724 
 725 
Live cell imaging 726 
Live cell imaging was performed for MDCKII ACVR1-IPF and NIH-3T3 ACVR1-727 
IPF cells on a Zeiss Invert 780 confocal microscope. Cells were plated on 35 mm 728 
Matek dishes and starved overnight in phenol-free, HEPES-buffered DMEM with 729 
0.5% FCS. During imaging, the temperature was maintained at 37oC. Data were 730 
acquired every 15 minutes over a time course. At each time point, a z-stack was 731 
acquired, and maximum intensity z-projections were quantified with ImageJ. 732 
 733 
Flow cytometry 734 
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MDCKII ACVR1-IPF and NIH-3T3 ACVR1-IPF cells were treated with ligand ± 735 
inhibitors. Twenty four hours post treatment, cells were trypsinized, washed and 736 
analyzed for GFP/YPF fluorescence on a LSRII flow cytometer (BD Biosciences), 737 
gated for viable, single cells. Treatment with FK506 (Sigma) was performed for 4 hr 738 
prior to analysis. 739 
 740 
Recombinant proteins, in vitro kinase assays and mapping of phospho-sites 741 
Recombinant SMAD proteins were expressed in E. coli and purified as previously 742 
described (Ross et al., 2006). Recombinant intracellular domains of ACVR1, 743 
BMPR1A and TGFBR1 which were expressed in insect cells were purchased from 744 
Carna Biosciences Inc (see Key Resources Table). Radioactive kinase reactions were 745 
performed with varying amounts of receptor (25–200 ng) at 37oC for 1 hr in a 20 µl 746 
reaction volume with 50 mM Tris-Cl (pH 7.5), 50 mM NaCl, 5 mM MnCl2 (ACVR1 747 
and TGFBR1) or MgCl2 (BMPR1A), 16.5 nM 32P--ATP (Perkin Elmer; 748 
NEG502A500UC) and either 200 µM or 50 µM cold ATP. Substrates were either the 749 
receptors themselves (autophosphorylation) or 2 µg of recombinant SMAD proteins. 750 
Reactions were stopped by adding Laemmli sample buffer and heating to 95°C for 5 751 
minutes. Proteins were resolved on a NuPAGE Novex 4-12% Bis-Tris gradient gel 752 
(Thermo Fisher) and stained with Colloidal Blue (Thermo Fisher). Gels were 753 
destained, dried and radioactivity measured by autoradiography. 754 
 To map phosphorylated residues on SMAD1, radioactive kinase reactions 755 
were performed in triplicate with 200 ng ACVRI, 2 µg recombinant SMAD1, 200 µM 756 
cold ATP, 0.33 µM 32P--ATP. For phospho-residue mapping, 32P-labelled SMAD1 757 
was digested with trypsin, the peptides were resolved by HPLC with an acetonitrile 758 
gradient and the 32P-labelled peptides eluted. Edman sequencing and mass-759 
spectrometry (Orbitrap Classic, Thermo Fisher) were then used to confirm phospho-760 
residues, as described previously (Campbell and Morrice, 2002), with the addition of 761 
multi-stage activation during the MS2 analysis. 762 
 763 
Chromatin immunoprecipitations, ChIP-Seq and motif enrichment 764 
Four million MDA-MB-231 or BT-549 cells were plated; 24 hr later, cells were 765 
starved overnight and the following day treated with TGF- or BMP-4. One 15 cm 766 
plate was used per immunoprecipitation. Chromatin immunoprecipitations, ChIP-seq 767 
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library preparation, next generation sequencing and data analysis were performed in 768 
biological duplicate essentially as previously described (Coda et al., 2017). In brief, 769 
ChIP-seq was performed on an Illumina HiSeq2500 generating 50 bp single end 770 
reads. Reads were aligned to the human GRCh37/hg19 genome assembly using BWA 771 
version 0.6 (Li and Durbin, 2009) with a maximum mismatch of 2 bases. Picard tools 772 
version 1.81 (http://sourceforge.net/projects/picard/) was used to sort, mark duplicates 773 
and index the resulting alignment bam files. Normalized tdf files for visualization 774 
purposes were created using IGVtools software (Robinson et al., 2011) 775 
(http://software.broadinstitute.org/software/igv/) by extending reads by 50 bp and 776 
normalizing to 10 million mapped reads per sample. Peaks were called by comparing 777 
stimulated samples to the respective untreated samples using MACS version 1.4.2 778 
(Zhang et al., 2008), using mfold change parameters of between 5 and 30. Peaks 779 
called by MACS were annotated using the annotatepeaks command in the Homer 780 
software (Heinz et al., 2010);  http://homer.salk.edu/homer/). 781 
 Peaks with less than 20 tags in the pSMAD1/5 IP after TGF- treatment or 782 
less than 30 tags in the SMAD3 IP after TGF- treatment were excluded from the 783 
analysis. In addition, peaks that had less than 1 tag per 10 bp in either of the above 784 
conditions were also excluded. Finally a ratio was taken between the number of tags 785 
in the pSMAD1/5 IP and the number of tags in the SMAD3 IP after TGF- treatment 786 
to determine the top 100 peaks with preferential SMAD1/5 binding. Of these, the top 787 
50 peaks with the highest density of tags per 10 bases in the pSMAD1/5 IP after TGF-788  treatment were used for more refined motif enrichment analysis and gene 789 
annotation. 790 
 Motif enrichment was performed using MEME (http://meme-suite.org/) with 791 
default parameters (zero or one occurrence per sequence, motifs between 6-50 bases 792 
in width). 793 
 794 
RNA-sequencing analysis in the NMuMG parental clone and SMAD1/5 clone 1 795 
NMuMG parental and SMAD1/5 clone 1 were plated, starved the next day in 796 
OptiMEM with 10 µg/ml insulin and treated for a further 48 hr with 2 ng/ml TGF-β. 797 
Total RNA was extracted as previously described (Gronroos et al., 2012), DNase I 798 
(Qiagen) treated and cleaned up with RNeasy columns (Qiagen). Biological triplicate 799 
libraries were prepared using the TruSeq RNA Library Prep Kit (Illumina) and were 800 
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single-end sequenced on Illumina HiSeq 2500 platform. Sequencing yield was 801 
typically ~80 million strand-specific reads per sample. The RSEM package (version 802 
1.2.31) (Li and Dewey, 2011) in conjunction with the STAR alignment algorithm 803 
(version 2.5.2a) (Dobin et al., 2013) was used for the mapping and subsequent gene-804 
level counting of the sequenced reads with respect to Ensembl mouse GRCm.38.86 805 
version genes. Normalization of raw count data and differential expression analysis 806 
was performed with the DESeq2 package (version 1.10.1) (Love et al., 2014) within 807 
the R programming environment (version 3.2.3) (R Development Core Team, 808 
2009). Genes were first identified as differentially expressed in the parental clone if 809 
they had more than 10 reads in either the untreated or TGF-β treated samples and a 810 
fold change between untreated and TGF- induced of > 1.5 or < 0.75 and FDR < 811 
0.05. An interaction contrast was then used to determine differentially regulated genes 812 
after TGF-β treatment in the parental clone versus SMAD1/5 clone 1. The resulting 813 
gene lists ranked by the Wald statistic were used to look for pathway and biological 814 
process enrichment using the Broad’s GSEA Tool (Subramanian et al., 2005). Genes 815 
with a fold difference between the two clones after TGF- treatment of  > 1.5 or  < 816 
0.75 and an FDR < 0.05 were judged to be dependent on SMAD1/5. 817 
 818 
Public availability of data 819 
The ChIP-seq data have been submitted to the NCBI Gene Expression Omnibus 820 
(GEO) under the accession number GSE92443. The RNA-seq data has been 821 
submitted to GEO under the accession number GSE103372. 822 
 823 
qPCR 824 
Oligonucleotides used are listed in Supplementary file 3. Total RNA extraction and 825 
reverse transcription were performed as previously described (Gronroos et al., 2012). 826 
The cDNA was diluted 10-fold and then used for quantitative PCR (qPCR). All 827 
qPCRs were performed with Express Sybr Greener (Thermo Fisher) with 300 nM of 828 
each primer and 2 µl of diluted cDNA or eluted immunoprecipitated chromatin. 829 
Fluorescence acquisition was performed on a 7500 FAST machine (Thermo Fisher). 830 
Quantification for relative gene expression was done using the comparative Ct 831 
method with target gene expression normalized to GAPDH. Quantification for ChIPs 832 
was performed using a standard curve and presented normalized to input. 833 
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 834 
Statistical analysis 835 
Western blots, immunofluorescence experiments and ChIP-PCRs are representative of 836 
at least two biological replicate experiments. All qPCRs are the mean and SEM of 837 
three independent biological experiments except gene expression after actinomycin D 838 
treatment and stimulation with TGF-3WW and TGF-3WD and validation of RNA-839 
sequencing results that are a representative of two independent experiments. 840 
Statistical analyses were performed with the unpaired Students T-Test, * p < 0.05, ** 841 
p < 0.01, *** p < 0.001, ns, non significant. 842 
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Figure legends 1114 
Figure 1. Characterization of SMAD1/5 phosphorylation by TGF-.  1115 
(A) MDA-MB-231 and NMuMG cells were treated with TGF- or BMP4 for the 1116 
times indicated.  1117 
(B) MDA-MB-231 cells were treated with TGF- for the times shown either alone or 1118 
after 5 minutes pre-treatment with cyclohexamide (CHX) or actinomycin D (Act D). 1119 
(C) MDA-MB-231 cells were treated with TGF- for 1 or 8 hr, and after 8 hr, cells 1120 
were re-stimulated with TGF- or BMP4 for 1 hr as shown in the scheme. For 1121 
comparison, cells were stimulated for 1 hr with BMP4.  1122 
 (D) MDA-MB-231 cells were induced or not with TGF- or BMP4 in the presence of 1123 
either 0.25 µM or 10 µM SB-431542 (SB) or 1 µM LDN-193189 (LDN) or a 1124 
combination of 0.25 µM or 10 µM SB-431542 and 1µM LDN-193189. In all panels 1125 
Western blots are shown probed with the antibodies indicated. B, BMP4, Un, 1126 
unstimulated. In B, SERPINE1, whose expression is induced by TGF-, provides a 1127 
control for the efficacy of the CHX and Act D. 1128 
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Figure 2. ACVR1 is activated by TGFBR1 in vitro and in vivo. 1130 
(A) The kinase domains of TGFBR1 and ACVR1 were analyzed alone or together in 1131 
an in vitro kinase reaction. SB-505124 and LDN-193189 were included as shown to 1132 
inhibit the activity of TGFBR1 and ACVR1 respectively. The autoradiograph is 1133 
shown in the top panel, with the Coomassie-stained gel below as a loading control.  1134 
(B) Schematic to show the domain organization of the Opto receptors. In Opto-1135 
TGFBR1*and Opto-ACVR1, the kinase domains of TGFBR1 and ACVR1 are fused 1136 
to the light sensitive LOV domain. At the N-terminus there is a myristylation domain 1137 
(indicated by the red zig zag). At the C-terminus there is an HA tag. The kinase 1138 
domain of TGFBR1 contains the activating mutation T204D. These Opto receptors 1139 
dimerize in the presence of blue light. 1140 
(C) NIH-3T3 cells were untransfected or transfected with FLAG-SMAD1 together 1141 
with either Opto-TGFBR1*, Opto-ACVR1 or both receptors together. Post 1142 
transfection, cells were either kept in the dark or exposed to blue light for 1 hr. Whole 1143 
cell extracts were Western blotted using antibodies against pSMAD1/5 (which detects 1144 
endogenous and FLAG pSMAD1/5), SMAD1 (which detects endogenous and FLAG 1145 
SMAD1), HA (to detect the Opto receptors) and Tubulin as a loading control. 1146 
(D) NIH-3T3 cells were untransfected or transfected with FLAG-SMAD1 together 1147 
with either Opto-TGFBR1*, Opto-ACVR1 or both receptors together. Post 1148 
transfection, cells were either kept in the dark or exposed to blue light for 1 hr. The 1149 
inductions were performed in the absence or presence of 0.5 µM LDN-193189 or 50 1150 
µM SB-505124 as indicated. Whole cell extracts were blotted as in (C). 1151 
(E) The experimental set up was as in (D) except that GFP-SMAD3 was used instead 1152 
of FLAG-SMAD1 to assess the activity of Opto-TGFBR1*.  1153 
(F) As in (C), except that an ACVR1 mutant in which all the threonines and serines of 1154 
the GS domain were mutated to valine or alanine respectively, was also assayed. 1155 
(G) As in (F), except that GFP-SMAD3 was used instead of FLAG-SMAD1. 1156 
Note that in all cases that the 1 hr induction with blue light led to reduced levels of the 1157 
transfected receptors and substrates.   1158 
 40 
 1159 
Figure 3. TGFBR1 and ACVR1 are present in distinct receptor complexes upon 1160 
TGF- stimulation. 1161 
(A) Alternative models of receptor clustering mediated by TGF-3 derivatives 1162 
capable of interacting with two pairs (TGF-3WW) or one pair (TGF-3WD) of type 1163 
II:type I receptors. If an obligate heterotetramer of two type I:type II pairs is required 1164 
for SMAD1/5 phosphorylation (Model I), then only TGF-3WW would lead to 1165 
SMAD1/5 phosphorylation. If TGF- induces higher order receptor clustering at the 1166 
cell surface (Model II), then both TGF-3WW and TGF-3WD would lead to SMAD1/5 1167 
phosphorylation.  1168 
(B) MDA-MB-231 cells were treated with different concentrations of TGF-3WW or 1169 
TGF-3WD for 1 hr as indicated. As a control, cells were either untreated (Un) or 1170 
treated with TGF-1 (T) or BMP4 (B) for 1 hr. Whole cell lysates were Western 1171 
blotted using the antibodies shown.  1172 
  1173 
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 1174 
Figure 4. ACVR1 is activated by TGF- in a TGFBR1-dependent manner.  1175 
(A and B) MDCKII ACVR1-IPF cells were imaged at 15 min intervals for 60 min 1176 
before the addition (arrow) of either media alone or media containing TGF- ± 10 µM 1177 
SB-431542 for a further 150 min. The panels in (A) are stills of the maximum 1178 
intensity projections at the times shown. The quantifications are shown in (B). The 1179 
fluorescence at the 60-min time point was taken as the reference that was subtracted 1180 
from all other time points. Data presented are the mean ± SD of three independent 1181 
fields. Statistical significance is shown for the indicated pairs of conditions at the 210 1182 
min timepoint.  1183 
(C) Fluorescence in MDCKII ACVR1-IPF cells assayed by flow cytometry 24 hr 1184 
after treatment. Each panel shows an overlay of the indicated treatment conditions. 1185 
The black line indicates the median of the untreated (Un) sample. Quantifications are 1186 
shown on the right. For each group, the percentage of cells greater than the median 1187 
fluorescence intensity of the untreated sample was quantified. Data are the mean ± 1188 
SEM of three independent experiments. SB, SB-431542 at 10 µM; Ab, antibody; 1189 
Nog, noggin; C, control antibody; B, blocking antibody.  1190 
 1191 
Figure 4 - Source data 1. Source data for ACVR1-IPF fluorescence (panel B) 1192 
Figure 4 - Source data 2. Source data for ACVR1-IPF fluorescence by flow cytometry 1193 
(panel C) 1194 
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 1197 
Figure 5. pSMAD1/5 is recruited to chromatin in response to TGF- and is most 1198 
highly enriched at GGCGCC motifs.  1199 
(A) MDA-MB-231 cells were either untreated (-) or treated with TGF- (+) for 1 hr. 1200 
Whole cell extracts were immunoprecipitated (IP) with the antibodies (Ab) indicated 1201 
or beads alone (Be). The IPs were Western blotted using the antibodies shown. Inputs 1202 
are shown on the left.  1203 
(B) IGV browser displays over the ID1, ID3 and JUNB loci after ChIP-Seq of MDA-1204 
MB-231 untreated (Un) and TGF--treated samples. IPs were performed with 1205 
antibodies against pSMAD1/5 (pS1/5), SMAD3 (S3) or with beads alone as a 1206 
negative control. Inputs are also shown. Red lines indicate regions validated in (C). U; 1207 
upstream peak; D1, downstream peak 1.  1208 
(C) Genomic regions were validated by ChIP-qPCR after treatment of MDA-MB-231 1209 
cells with TGF- (T) or BMP4 (B) for the times shown. IPs were as in (B). A 1210 
representative experiment of two performed in triplicate is shown with means ± SD. 1211 
(D) The most enriched motif obtained from a MEME-ChIP analysis of the top 100 1212 
pSMAD1/5 peaks. 1213 
(E) Proportion of variants of the GGCGCC motif identified in the top 100 pSMAD1/5 1214 
peaks. 1215 
 1216 
Figure 5 - Source data 1. ChIP-seq datasets 1217 
Figure 5 - Source data 2. ChIP-PCR data for graphs in panel C 1218 
 1219 
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 1222 
Figure 6. SMAD1/5 is required for TGF--induced EMT. 1223 
(A) The parental NMuMG clone and the ΔSMAD1/5 clone 1 were treated with TGF-1224  or BMP4 for the times shown. Whole cell extracts were immunoblotted with the 1225 
antibodies indicated.    1226 
(B) Parental NMuMG clone and the ΔSMAD1/5 clone 1 cells were left untreated or 1227 
treated with TGF- for 48 hr and imaged after indirect immunofluorescence (IF) 1228 
using antibodies against TJP1 and CDH1. A merge of the two with DAPI in blue is 1229 
also shown.  1230 
(C) NMuMG cells were left untreated (Un) or treated with TGF- alone or in 1231 
combination with 1 µM LDN-193189 (LDN) ± 0.125 µM SB-431542 (SB) for 48 hr. 1232 
Panels show cells imaged under either phase contrast (left panels) or by indirect 1233 
immunofluorescence (IF) using antibodies against TJP1 and CDH1. A merge of the 1234 
two with DAPI in blue is also shown.  1235 
(D) NMuMG cells were left untreated or treated with TGF- alone or in combination 1236 
with either 1 µM LDN-193189  ± 0.125 µM SB-431542 for 48 hr. Whole cell lysates 1237 
were immunoblotted with the indicated antibodies.  1238 
(E) EpRas cells were left untreated (Un) or treated with TGF- alone or in 1239 
combination with 1 µM LDN-193189 (LDN) ± 0.125 µM SB-431542 (SB) for 9 days, 1240 
then imaged after indirect immunofluorescence (IF) using antibodies against TJP1 1241 
and CDH1 or a merge of the two with DAPI in blue.  1242 
(F) EpRas cells were left untreated or treated with TGF- for 1 hr alone or with 1243 
combinations of 1 µM LDN-193189, 0.125 µM SB-431542 or 10 µM SB-431542 as 1244 
indicated. Whole cell lysates were immunoblotted with the indicated antibodies 1245 
In (B), (C) and (E) the indirect IF images are maximum intensity projections of a z-1246 
stack in each channel. 1247 
 1248 
Figure 6 - Source data 1. RNA-seq datasets 1249 
 1250 
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 1252 
Figure 7. TGF--induced ID1 via pSMAD1/5 is required for EMT.  1253 
(A) NMuMG cells were transfected with siRNAs against ID1 or NT control, then left 1254 
untreated or treated with TGF- for 24 hr. Cells were imaged after indirect IF with 1255 
antibodies against TJP1 and CDH1 or a merge of the two with DAPI in blue. All 1256 
indirect IF images are maximum intensity projections of a z-stack in each channel.  1257 
(B) Western blots to show knockdown efficiency of the ID1 siRNA. NMuMG cells 1258 
were treated with TGF- (T) or BMP4 (B) for 1 hr.  1259 
(C) The model shows combinatorial signaling by TGF- utilizing complexes 1260 
containing two different type I receptors. Type II receptors are shown in blue, 1261 
TGFBR1 in orange and ACVR1 in green as in Figure 3A. P denotes phosphorylation. 1262 
S1/5, SMAD1/5; S2/3, SMAD2/3; S4, SMAD4. The question mark indicates that we 1263 
do not yet know the function of the mixed R-SMAD complexes in the physiological 1264 
responses. For discussion, see text. 1265 
 1266 
  1267 
 45 
 1268 
Figure 1 – figure supplement 1. SMAD1 phosphorylation kinetics in response to 1269 
TGF-.  1270 
(A, C–E) Western blots are shown probed with the indicated antibodies.  1271 
(A) BT-549 cells were grown as a monolayer on plastic (2D) or as spheres in low 1272 
attachment plates (phase contrast images on the right) and treated with TGF- or 1273 
BMP4 for the times indicated. BT-549 cells show sustained SMAD1/5 1274 
phosphorylation in response to TGF-.  1275 
(B) qPCR of the indicated genes in MDA-MB-231 cells treated with actinomycin D 1276 
for the times shown. Data are presented as fold change relative to 0 hr. A 1277 
representative experiment performed in triplicate is shown with means ± SD. 1278 
Transcripts of both TGFBRI and TGFBR2 are relatively stable.  1279 
 (C) NMuMG cells were treated with TGF- for the times shown either alone or after 1280 
5 minutes pre-treatment with cyclohexamide (CHX) or actinomycin D (Act D). Act D 1281 
prolongs, while CHX terminates both SMAD1/5 and SMAD2 phosphorylation in 1282 
response to TGF-. Un, untreated.  1283 
(D) NMuMG cells were treated with TGF- for 1 or 8 hr and after 8 hr, cells were 1284 
restimulated with 10 or 20 ng/ml BMP4 as shown in the scheme. Cells were also 1285 
treated for 1 hr with 10 or 20 ng/ml BMP4 as a control. Cells pre-treated with TGF- 1286 
can still be stimulated with BMP4.  1287 
 (E) NMuMG cells were left untreated or treated with TGF- ± SB-431542 (SB; 1288 
0.125 µM or 10 µM) ± 1 µM LDN-193189 (LDN) or BMP4 ± 1 µM LDN-193189 for 1289 
1 hr. The kinase activity of both classes of type I receptors is required for SMAD1/5 1290 
phosphorylation by TGF-.  1291 
 1292 
Figure 1 – figure supplement 1 - Source data 1. Source data for qPCRs (panel B) 1293 
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 1296 
Figure 1 - figure supplement 2. SMAD1 is efficiently phosphorylated by ACVR1 1297 
and BMPR1A, but poorly phosphorylated by TGFBR1.  1298 
(A) In vitro kinase assays using the kinase domains of ACVR1, BMPR1A, and 1299 
TGFBR1 at 200, 100, 50, 25 ng with recombinant SMAD1 (S1) or SMAD2 (S2) as 1300 
substrates. Top panels, autoradiograph; bottom panels, Coomassie-stained gel.  1301 
(B) Incorporation of 32P into SMAD1 and SMAD2 catalysed by ACVR1 and 1302 
TGFBR1 using different specific activities of [32P]-ATP. A constant amount of 1303 
[32P]-ATP was added into the kinase reaction with either 200 or 50 µM cold ATP. 1304 
Top panels, autoradiograph; bottom panels, Coomassie-stained gel. Numbers 1305 
underneath indicate the fold changes relative to the 32P incorporation in SMAD1 1306 
(upper) or SMAD2 (lower) catalyzed by TGFBR1 using 200 µM cold ATP. The 1307 
phosphorylation of SMAD1 and 2 by ACVR1 and TGFBR1 was dependent  on the 1308 
specific activity of the [32P]-ATP, whilst the apparent phosphorylation of SMAD1 1309 
by TGFBR1 is not, suggesting that it is non-specific. 1310 
(C) Mapping ACVR1 phosphorylation sites on SMAD1. Full length SMAD1 1311 
phosphorylated by ACVR1 was digested with trypsin. Peptides were resolved by 1312 
reverse phase HPLC (left panel). The C-terminal peptide of SMAD1 existed in three 1313 
different phosphorylation states (peptides a, b, and c); the three subsequent peaks are 1314 
tryptic miscleavage products. The phosphorylation sites in the peptides were mapped 1315 
using solid phase Edman sequencing (panels labelled a, b and c). The deduced 1316 
phosphorylation sites in the SSVS motif in the individual peptides are shown in red.  1317 
  1318 
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Figure 2 - figure supplement 1. Kinase dead Opto-TGFBR1 cannot activate 1319 
Opto-ACVR1.  1320 
(A) NIH-3T3 cells were untransfected or transfected with FLAG-SMAD1 together 1321 
with Opto-TGFBR1*, Opto-ACVR1 or both receptors together or a kinase-dead 1322 
version of Opto-TGFBR1 (Opto-TGFBR1-KR) alone or together with Opto-ACVR1. 1323 
Post transfection, cells were either kept in the dark or exposed to blue light for 1 hr. 1324 
Whole cell extracts were Western blotted using antibodies against pSMAD1/5 (which 1325 
detects endogenous and FLAG pSMAD1/5), SMAD1 (which detects endogenous and 1326 
FLAG SMAD1), HA (to detect the Opto receptors) and Tubulin as a loading control. 1327 
(B) The experimental set up was as in (A) except that GFP-SMAD3 was used instead 1328 
of FLAG-SMAD1 to assess the activity of Opto-TGFBR1* and Opto-TGFBR1-KR. 1329 
The band marked with an asterisk is a background band. 1330 
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Figure 3 – figure supplement 1. NMuMG cells respond to both TGF-3WW and 1333 
TGF-3WD.  1334 
NMuMG cells were untreated (Un) or treated with TGF-1 (T), BMP4 (B) or the 1335 
indicated concentrations of TGF-3WW and TGF-3WD for 1 hr. Whole cell lysates 1336 
were immunoblotted with the antibodies shown. Both TGF-3WW and TGF-3WD 1337 
induce phosphorylation of pSMAD1/5, although the latter is less potent. 1338 
 1339 
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 1341 
Figure 4 – figure supplement 1. Characterization of cells stably transfected with 1342 
the ACVR1-IPF. 1343 
(A) NMuMG cells knocked out for ACVR1 and BMPR1A were transfected with 1344 
either empty vector (pcDNA3.1 Hygro +), ACVR1-IPF or ACVR1-FLAG. Whole 1345 
cell extracts were Western blotted for pSMAD1/5, SMAD1 and GFP and FLAG. 1346 
Actin is a loading control. 1347 
(B) MDCKII ACVR1-IPF or NIH-3T3 ACVR1-IPF cells imaged by indirect IF with 1348 
an antibody against GFP (red) with nuclei stained with DAPI (blue). The controls 1349 
were a secondary antibody only sample (left) and the matched empty vector-1350 
transfected cells stained with the GFP antibody (middle). Scale bar equates to 20 µM. 1351 
ACVR1-IPF localizes to the membrane in both cell types, with basolateral 1352 
localisation in the MDCKII cells.  1353 
(C and D) The MDCKII  or NIH-3T3 cell lines shown in (B) were treated with TGF- 1354 
or BMP4 for the times indicated. Whole cell lysates were immunoblotted with the 1355 
indicated antibodies. Stable transfection of ACVR1-IPF does not affect the 1356 
phosphorylation kinetics of SMAD1/5 in response to TGF- or BMP.  1357 
(E) Median fluorescence intensity (y-axis) as measured by flow cytometry of 1358 
MDCKII ACVR1-IPF cells treated with the indicated concentrations of FK506 for 4 1359 
hr. FK506 activates ACVR1-IPF fluorescence in a dose-dependent manner.  1360 
(F) Quantification of NIH-3T3 ACVR1-IPF cells imaged at 30-minute intervals for a 1361 
total of 210 min after the addition of either media alone or media containing TGF- ± 1362 
10 µM SB-431542. Data presented are the mean ± SD of three independent fields. 1363 
Statistical significance is shown for the indicated pairs of conditions at the 210 min 1364 
timepoint.  1365 
(G) Fluorescence in NIH-3T3 ACVR1-IPF cells assayed by flow cytometry 24 hr 1366 
after being treated with media alone or with TGF- ± 10 µM SB-431542 (SB). The 1367 
percentage of cells with fluorescence greater than the median fluorescence intensity of 1368 
the untreated sample (-) was quantified. Data are presented as the mean ± SEM of 1369 
three independent experiments.  1370 
 1371 
Figure 4 - figure supplement 1 - Source data 1. Source data for ACVR1-IPF 1372 
fluorescence by flow cytometry (panel E) 1373 
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 1374 
Figure 4 - figure supplement 1 - Source data 2. Source data for ACVR1-IPF 1375 
fluorescence (panel F) 1376 
Figure 4 - figure supplement 1 - Source data 3. Source data for ACVR1-IPF 1377 
fluorescence by flow cytometry (panel G) 1378 
 1379 
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 1381 
Figure 5 – figure supplement 1. Chromatin binding of pSMAD1/5 and SMAD3.  1382 
(A) IGV browser displays around the ID4, ATOH8, PMEPA1, BHLHE40 and 1383 
SERPINE1 loci after ChIP-Seq for SMAD3 (S3) and pSMAD1/5 (pS1/5) in MDA-1384 
MB-231 cells. Untreated and TGF--treated samples and the inputs are shown. IPs 1385 
were performed with beads as a negative control. Red lines indicate genomic regions 1386 
validated by ChIP-qPCR after treatment of MDA-MB-231 cells with TGF- (T) or 1387 
BMP4 (B) for the times indicated (right panels). U, upstream peak; U1, upstream 1388 
peak 1. In response to TGF-, pSMAD1/5 bound transiently at the ID4 and ATOH8 1389 
loci while SMAD3 bound stably to PMEPA1 over the same time course.  1390 
(B) ChIP-qPCR of the indicated loci after treatment of BT-549 cells with TGF- (T) 1391 
or BMP4 (B) for 1 hr. IPs were as in (A). In response to TGF-, pSMAD1/5 bound 1392 
strongly around the ID loci while SMAD3 bound strongly to the JUNB upstream 1393 
locus. In A and B a representative experiment of two performed in triplicate is shown 1394 
with means ± SD.  1395 
(C) The most enriched motif obtained from a MEME-ChIP analysis of the top 50 1396 
pSMAD1/5 peaks. The canonical SMAD1/5:SMAD4 binding element is strongly 1397 
enriched in these peaks. 1398 
 1399 
Figure 5 – figure supplement 1 - Source data 1. ChIP-PCR data for graphs in panel A 1400 
Figure 5 – figure supplement 1 - Source data 2. ChIP-PCR data for graphs in panel B 1401 
 1402 
 1403 
 1404 
  1405 
 52 
 1406 
Figure 5 – figure supplement 2. ID1 and ID3 are TGF--induced target genes 1407 
that require the pSMAD1/5 signaling arm.  1408 
(A) Western blots showing knockdown efficiency in MDA-MB-231s of the siRNAs 1409 
shown. S3, SMAD3; S4, SMAD4; S1/5, SMAD1/5; NT, non targeting. Cells were 1410 
untreated (U) or treated with TGF- (T) or BMP4 (B) for 1 hr. Lysates were 1411 
immunoblotted using the antibodies shown.  1412 
(B) MDA-MB-231 cells were transfected with siRNAs against the indicated SMADs 1413 
or a non-targeting control (NT) and then treated with TGF- (T) or BMP4 (B) for 1 1414 
hr. Un, untreated.  1415 
(C) MDA-MB-231 cells were left untreated or treated with TGF- ± SB-431542 (SB; 1416 
0.25 µM or 10 µM) ± 1 µM LDN-193189 (LDN) or BMP4 ± 1 µM LDN-193189 for 1417 
1 hr. In B and C, gene expression was measured by qPCR. Data are presented as fold 1418 
change relative to the untreated NT sample in B and to the (-) sample in (C) and are 1419 
the means ± SEM of three independent experiments. Statistical significance is shown 1420 
for selected comparisons. 1421 
(D) NMuMG cells were treated with TGF- or BMP4 ± the inhibitors indicated. Gene 1422 
expression was measured by qPCR. The combination of 0.125 µM SB-431542 (SB) 1423 
and 1 µM LDN-193189 (LDN) inhibited TGF--induced Id1 and Id3 expression 1424 
without affecting JunB expression. The data are means ± SEM of at least two 1425 
independent experiments. Statistical significance is shown for selected comparisons.  1426 
 (E) MDA-MB-231 cells were treated with TGF-1 (T), BMP4 (B) or different 1427 
concentrations of  TGF-3WW and TGF-3WD for 1 hr as in Figure 3B. Gene 1428 
expression was measured by qPCR. Both TGF-3WW and TGF-3WD led to the 1429 
induction of ID1, ID3 and JUNB, although the induction by TGF-3WD was weaker. 1430 
A representative experiment of two, performed in triplicate is shown with means ± 1431 
SD. 1432 
 1433 
Figure 5 - figure supplement 2 - Source data 1. qPCR data for graphs in panel B 1434 
Figure 5 - figure supplement 2 - Source data 2. qPCR data for graphs in panel C 1435 
Figure 5 - figure supplement 2 - Source data 3. qPCR data for graphs in panel D 1436 
Figure 5 - figure supplement 2 - Source data 4. qPCR data for graphs in panel E 1437 
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Figure 6 – figure supplement 1.  Characterization of the NMuMG ΔSMAD1/5 1439 
clones. 1440 
(A) Sequences of SMAD1 and SMAD5 in the regions around the guides in NMuMG 1441 
ΔSMAD1/5 clone 1. From our sequencing we conclude that there are two alleles of 1442 
SMAD1 and 3 alleles of SMAD5 in NMuMG cells. The protein sequence for the wild 1443 
type (WT) is shown in red above the DNA sequence. Frame shifts are evident in both 1444 
SMAD1 mutant alleles, and all three SMAD5 alleles. 1445 
(B) The parental NMuMG clone and the ΔSMAD1/5 clone 2 were treated with TGF-1446  or BMP4 for the times shown. Whole cell extracts were immunoblotted with the 1447 
antibodies indicated.    1448 
(C) Sequences of SMAD1 and SMAD5 in the regions around the guides in NMuMG 1449 
ΔSMAD1/5 clone 2. The protein sequence for the wild type (WT) is shown in red 1450 
above the DNA sequence. This clone exhibits no pSMAD1/5 in reponse to either 1451 
TGF- or BMP4 (see panel B), despite having a single allele of SMAD1 and SMAD5 1452 
with an in-frame deletion of a single amino acid. This is readily explained by the 1453 
nature of those mutations, which likely lead to unfolded proteins. Mutant SMAD1 1454 
allele 1 is deleted for the conserved amino acid Y125 in the MH1 domain, which is 1455 
adjacent to H126, that is responsible for chelating a Zn ion in the zinc finger 1456 
(BabuRajendran et al., 2010). Mutant SMAD5 allele 1 is deleted for the conserved 1457 
amino acid V283 which is in -sheet 2 of the MH2 domain, which is critical for 1458 
folding of this domain (Wu et al., 2001, Qin et al., 2001). In SMAD1 allele 1 the 1459 
insert length is 124 bp and in SMAD5 allele 3, it is 59 bp. 1460 
(D) Parental NMuMG clone and the ΔSMAD1/5 clone 2 cells were treated with or 1461 
without TGF- for 48 hr, fixed and imaged following indirect immunofluorescence  1462 
(IF) using antibodies against TJP1 and CDH1. A merge of the two with DAPI in blue 1463 
is also shown. The indirect IF images are maximum intensity projections of a z-stack 1464 
in each channel. 1465 
 1466 
  1467 
 54 
Figure 6 – figure supplement 2. Validation of SMAD1/5-dependent TGF- 1468 
induced genes. 1469 
NMuMG parental clone and NMuMG ΔSMAD1/5 clone 1 cells were untreated or 1470 
treated with TGF- for the times shown. Total RNA was extracted and qPCR was 1471 
used to assay the levels of mRNA for the genes shown. The data shown are from a 1472 
representative experiment (means ± SD).  1473 
 1474 
Figure 6 - figure supplement 2 - Source data 1. qPCR data for all graphs shown. 1475 
  1476 
 55 
Figure 6 – figure supplement 3. The pSMAD1/5 signaling arm is required for 1477 
TGF--mediated EMT.  1478 
(A) NMuMG cells were transfected with non-targeting (NT) or siRNAs against the 1479 
SMADs as indicated. Cells were then left untreated or treated with TGF- for 24 hr. 1480 
Cells were imaged after indirect IF with antibodies against TJP1 and CDH1. A merge 1481 
of the two with DAPI in blue is also shown. All indirect IF images are maximum 1482 
intensity projections of a z-stack in each channel. SMAD1/5, SMAD3 and SMAD4 1483 
are all required for TGF--induced EMT. 1484 
(B) Western blots to show knockdown efficiency of the siRNAs. NMuMG cells were 1485 
untreated (Un) or treated with TGF- (T) or BMP4 (B) for 1 hr. Lysates were 1486 
immunoblotted using the antibodies shown.  1487 
 (C) NMuMG cells were treated with ligands or inhibitors as indicated. Cell lysates 1488 
were immunoblotted using the antibodies shown. A combination of 0.125 µM SB-1489 
431542 and 1 µM LDN-193189 or 0.125 µM SB-431542 and 1 µM DMH1 was 1490 
sufficient to abolish the TGF--induced phosphorylation of SMAD1/5.  1491 
(D) NMuMG cells were either untreated (Un) or treated with TGF- ± 1 µM DMH1 ± 1492 
0.125 µM SB-431542 (SB) for 48 hr. Cells were fixed and stained for TJP1 and 1493 
CDH1. In the merge, DAPI (blue) marks the nuclei. DMH1 is sufficient to inhibit 1494 
TGF--induced EMT.  1495 
 1496 
 1497 
 1498 
  1499 
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Figure 7 – figure supplement 1. TGF--induced ID1 is required for EMT.  1500 
(A)  NMuMG, BT-549 and MDA-MB-231s were treated with ligands as shown and 1501 
lysates were immunoblotted using the antibodies indicated. The induction of ID1 1502 
correlates with pSMAD1/5 phosphorylation.  1503 
(B) NMuMG cells were transfected with non-targeting (NT) or individual siRNAs 1504 
against the Id1 as indicated. Cells were then left untreated or treated with TGF- for 1505 
48 hr. Cells were imaged after indirect IF with antibodies against TJP1 and CDH1. A 1506 
merge of the two with DAPI in blue is also shown. All indirect IF images are 1507 
maximum intensity projections of a z-stack in each channel. Knockdown of ID1 by 1508 
any of the siRNAs inhibits TGF--induced EMT. 1509 
(C) NMuMG cells were transfected with siRNAs as in (B). They were uninduced or 1510 
induced with BMP4 for 1 hr to induce expression of ID1 in control-transfected cells. 1511 
Whole cell extracts were immunoblotted for the proteins indicated.   1512 
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 1513 
Supplementary Movie legends 1514 
 1515 
Video 1. Fluorescence in MDCKII ACVR1-IPF cells treated with media alone. 1516 
MDCKII ACVR1-IPF cells were imaged for 1 hr prior to the addition of media alone 1517 
followed by imaging for a further 2.5 hr. Very little increase in fluorescence was 1518 
observed over the time course. 1519 
 1520 
Video 2. Fluorescence in MDCKII ACVR1-IPF cells treated with TGF-. 1521 
MDCKII ACVR1-IPF cells were imaged for 1 hr prior to the addition of 2 ng/ml 1522 
TGF- followed by imaging for a further 2.5 hr. Significant increase in fluorescence 1523 
was observed over the time course with intracellular puncta of fluorescence becoming 1524 
more evident over time. 1525 
 1526 
Video 3. Fluorescence in MDCKII ACVR1-IPF cells treated with TGF- and SB-1527 
431542. MDCKII ACVR1-IPF cells were imaged for 1 hr prior to the addition of 2 1528 
ng/ml TGF- + 10 M SB-431542 to the cells followed by imaging for a further 2.5 1529 
hr. Very little increase in fluorescence was observed over the time course.  1530 
 1531 
Video 4. Fluorescence in NIH-3T3 ACVR1-IPF cells treated with media alone. 1532 
NIH-3T3 ACVR1-IPF cells were imaged for 3.5 hr after the addition of media alone. 1533 
A modest and gradual increase in fluorescence was observed over the time course.  1534 
 1535 
Video 5. Fluorescence in NIH-3T3 ACVR1-IPF cells treated with TGF-. NIH-1536 
3T3 ACVR1-IPF cells were imaged for 3.5 hr after the addition of 2 ng/ml TGF-. A 1537 
significant increase in fluorescence was observed over the time course with 1538 
fluorescence becoming more evident on membrane projections and intracellular 1539 
vesicles over time. 1540 
 1541 
Video 6. Fluorescence in NIH-3T3 ACVR1-IPF cells treated with TGF- and SB-1542 
431542. NIH-3T3 ACVR1-IPF cells were imaged for 3.5 hr after the addition of 2 1543 
ng/ml TGF- + 10 M SB-431542. A modest and gradual increase in fluorescence 1544 
was observed over the time course. 1545 
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Supplementary Files 1546 
 1547 
Supplementary File 1. Sequence of Opto-TGFBR1* 1548 
Supplementary File 2. Sequence of Opto-ACVR1 1549 
Supplementary File 3. List of oligonucleotides and siRNAs 1550 
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